The Pharmaceutical Benefits Advisory Committee (PBAC) will consider adding ocrelizumab (Ocrevus®) via subcutaneous delivery to the PBS for relapsing remitting MS.
As Australians head toward the 2025 Federal Election, The Raw Nerve, MS Australia’s official podcast, gathered leading experts to explore a crucial question: why should health be a top election priority?
A new international effort to prevent multiple sclerosis (MS) is officially underway, as researchers, clinicians, people living with MS, and MS organisations from around the world gather in Lisbon, Portugal, for the inaugural Global Prevention and Early Detection Initiative workshop.
We are on the cusp of May, the most important month in the global MS calendar.
Researchers have discovered that genetic changes accumulate more rapidly in MS brain lesions than in non-lesion tissue, with distinct patterns emerging in the lesions.
A pilot study has found an existing online cognitive behavioural therapy (CBT) program from Germany is highly acceptable to people with multiple sclerosis (MS) in Australia and achieved reduced levels of MS-related fatigue.
Phase 3 trials did not show a clear advantage of evobrutinib compared to current treatments for people with relapsing MS.
Luigi wanted his legacy to be one that made a difference. Through his generous bequest to MS Plus, he ensured that people living with multiple sclerosis would receive the support they need to live fuller, more independent lives.
The Federal Government has announced the listing of ravulizumab (Ultomiris®) on the Pharmaceutical Benefits Scheme (PBS) for the treatment of adults with neuromyelitis optica spectrum disorders (NMOSD). This is a historic milestone as ravulizumab is the first-ever treatment specifically for NMOSD to be included on the PBS.
